On March 24, 2016, the US Food and Drug Administration (FDA) published draft guidance to assist applicants who intend to file abbreviated new drug applications (ANDAs) for approval of generic versions of opioid drug products with abuse-deterrent properties.  The FDA’s draft guidance follows its April 2015 final guidance for brand name opioids, which marked the … Continue reading